Jason Breen, Partner, Wilson Sonsini
Jason Breen is a partner in the Los Angeles office of Wilson Sonsini, where he represents public and private companies at all stages of growth in M&A transactions, primarily working with clients in the life sciences and technology industries. Jason also represents venture capital, growth equity, and private equity funds and focuses on other strategic transactions, including divestitures, joint ventures, and financings. Throughout his career, Jason has represented a broad spectrum of companies in pivotal M&A transactions. This includes assisting biotech companies like DTx Pharma and XinThera in their sale to Novartis and Gilead respectively, guiding AI healthcare leader Caption Health in its sale to GE Healthcare, and overseeing Amphastar Pharmaceuticals in its acquisition of Eli Lilly’s low blood sugar drug BAQSIMI. Jason has also supported Obsidio, a medical device company, in its sale to Boston Scientific and Novosteo, a clinical-stage biopharmaceutical company, in its sale to Cortexyme. Prior to joining Wilson Sonsini, Jason was an equity partner at Goodwin Procter’s Los Angeles office and began his legal career at Simpson Thacher & Bartlett LLP in New York. A distinguished figure in corporate law, Jason was honored as the “Corporate Attorney of the Year” by the Los Angeles Business Journal in 2019. He holds a J.D. with honors from UCLA School of Law and a B.S. in Applied Mathematics from Harvard University.
